前列腺癌SBRT联用与不联用瘤内加量的尿道膀胱剂量学及泌尿毒性
这项回顾性队列研究分析了2018至2023年间349例局限期前列腺癌患者,其中266例接受SBRT联合瘤内加量(IPB),83例仅接受SBRT。两组尿道和膀胱剂量学参数均无统计学显著差异,IPB组3级及以上晚期泌尿毒性发生率为2.25%,无IPB组为2.47%,且无3级急性毒性报告。结果表明IPB联用SBRT对优势前列腺内病灶进行局灶剂量提升是可行且安全的。
要点
- IPB联合SBRT与单纯SBRT的尿道和膀胱剂量学参数无显著差异。
- IPB组3级及以上晚期泌尿毒性发生率为2.25%,无IPB组为2.47%。
- 两组均未报告3级急性泌尿毒性,支持IPB联用SBRT的安全性。
核心结论
- SBRT联合瘤内加量对优势前列腺内病灶进行局灶剂量提升是可行且安全的,未显著增加尿道或膀胱剂量及毒性。
研究设计与样本
- 回顾性队列研究纳入349例局限期前列腺癌患者,266例接受SBRT联合IPB,83例接受单纯SBRT,采用机器人SBRT平台联合基准标记追踪治疗。
主要发现
- 两组尿道D0.03cc、D0.3cc、V40Gy及膀胱D0.03cc、D5cc、D10cc、V37Gy的中位数比较均无统计学显著差异。
- IPB组3级及以上晚期泌尿毒性发生率为2.25%,无IPB组为2.47%。
- 两组均未报告3级急性泌尿毒性。
关键数值与推荐
- 尿道剂量学参数包括D0.03cc、D0.3cc和V40Gy,膀胱剂量学参数包括D0.03cc、D5cc、D10cc和V37Gy。
- 急性和晚期毒性采用CTCAE标准评估,3级及以上晚期泌尿毒性为关键安全性指标。
临床怎么用
- 对于局限期前列腺癌,可考虑在SBRT基础上联合IPB对优势前列腺内病灶进行局灶剂量提升,同时关注尿道和膀胱剂量约束。
局限性
- 本研究为回顾性队列研究,未来需前瞻性研究IPB联合SBRT的毒性和生活质量,并标准化优势病灶勾画及探索自适应计划技术。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the dosimetric and toxicity profiles of stereotactic body radiotherapy (SBRT) for prostate cancer, comparing cohorts with and without intraprostatic boost (IPB) to assess feasibility and safety of IPB, with particular attention to urethral and bladder dose and toxicity. MATERIALS AND METHODS: This retrospective cohort study analyzed 349 patients with localized prostate cancer treated between 2018 and 2023. Of these, 266 received SBRT with IPB, and 83 received SBRT without IPB. Patients were treated using a robotic SBRT platform with fiducial tracking. Dosimetric parameters for the urethra, including D0.03cc, D0.3cc, and V40Gy, and for the bladder, including D0.03cc, D5cc, D10cc, and V37Gy, were evaluated. Acute and late toxicities were assessed using CTCAE criteria. RESULTS: For the urethra, median values for D0.03cc, D0.3cc, and V40Gy, and for the bladder, median values D0.03cc, D5cc, D10cc, and V37Gy were compared and no statistically significant differences were observed between the two cohorts. Late urinary toxicity of grade 3 or higher occurred in 2.25 % of patients in the IPB group and 2.47 % in the no IPB group, with no grade 3 acute toxicities reported. DISCUSSION: These findings support the use of SBRT using an IPB as a feasible and safe approach to achieve focal dose escalation to dominant intra-prostatic lesions (DILs) without significantly increasing urethra or bladder dose or toxicity. Future research should focus on standardizing DIL contouring, exploring adaptive planning techniques to increase accuracy, and prospectively studying toxicity and quality of life in patients treated with IPB with SBRT.
引用
- Bhargava N, Hurwitz M, Levey J, et al. Urethral and bladder dosimetry and urinary toxicity in prostate cancer patients undergoing SBRT with and without intra-prostatic boost. Clin Transl Radiat Oncol. 2025. PMID: 40607005. doi:10.1016/j.ctro.2025.100993
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。